Rare patients with familial hypercholesterolemia (FH) that possess mutations in both the PCSK9 and LDLR gene have a significantly higher risk of future coronary heart disease (CHD) compared to FH patients bearing mutation in only one of the two genes [4]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.